The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Major Depressive Disorder (MDD)-Global Market Insights and Sales Trends 2024
Synopsis
Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person's ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
The global Major Depressive Disorder (MDD) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Major Depressive Disorder (MDD) in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Major Depressive Disorder (MDD) market. Antidepressant Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the SSRIs segment is estimated at % CAGR for the next seven-year period.
The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Major Depressive Disorder (MDD), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Major Depressive Disorder (MDD) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Major Depressive Disorder (MDD) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Major Depressive Disorder (MDD) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Major Depressive Disorder (MDD) covered in this report include Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Eli Lily, Johnson & Johnson, Forest Laboratories, Sanofi-Aventis and H. Lundbeck, etc.
The global Major Depressive Disorder (MDD) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
GlaxoSmithKline
Merck
AstraZeneca
Eli Lily
Johnson & Johnson
Forest Laboratories
Sanofi-Aventis
H. Lundbeck
Bristol-Myers Squibb
Global Major Depressive Disorder (MDD) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Major Depressive Disorder (MDD) market, Segment by Type:
Antidepressant Drugs
SSRIs
SNRIs
Benzodiazepines
Others
Global Major Depressive Disorder (MDD) market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Major Depressive Disorder (MDD) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person's ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
The global Major Depressive Disorder (MDD) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Major Depressive Disorder (MDD) in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Major Depressive Disorder (MDD) market. Antidepressant Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the SSRIs segment is estimated at % CAGR for the next seven-year period.
The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Major Depressive Disorder (MDD), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Major Depressive Disorder (MDD) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Major Depressive Disorder (MDD) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Major Depressive Disorder (MDD) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Major Depressive Disorder (MDD) covered in this report include Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Eli Lily, Johnson & Johnson, Forest Laboratories, Sanofi-Aventis and H. Lundbeck, etc.
The global Major Depressive Disorder (MDD) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
GlaxoSmithKline
Merck
AstraZeneca
Eli Lily
Johnson & Johnson
Forest Laboratories
Sanofi-Aventis
H. Lundbeck
Bristol-Myers Squibb
Global Major Depressive Disorder (MDD) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Major Depressive Disorder (MDD) market, Segment by Type:
Antidepressant Drugs
SSRIs
SNRIs
Benzodiazepines
Others
Global Major Depressive Disorder (MDD) market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Major Depressive Disorder (MDD) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Major Depressive Disorder (MDD)
1.1 Major Depressive Disorder (MDD) Market Overview
1.1.1 Major Depressive Disorder (MDD) Product Scope
1.1.2 Major Depressive Disorder (MDD) Market Status and Outlook
1.2 Global Major Depressive Disorder (MDD) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Major Depressive Disorder (MDD) Market Size by Region (2018-2029)
1.4 Global Major Depressive Disorder (MDD) Historic Market Size by Region (2018-2023)
1.5 Global Major Depressive Disorder (MDD) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Major Depressive Disorder (MDD) Market Size (2018-2029)
1.6.1 North America Major Depressive Disorder (MDD) Market Size (2018-2029)
1.6.2 Europe Major Depressive Disorder (MDD) Market Size (2018-2029)
1.6.3 Asia-Pacific Major Depressive Disorder (MDD) Market Size (2018-2029)
1.6.4 Latin America Major Depressive Disorder (MDD) Market Size (2018-2029)
1.6.5 Middle East & Africa Major Depressive Disorder (MDD) Market Size (2018-2029)
2 Major Depressive Disorder (MDD) Market by Type
2.1 Introduction
2.1.1 Antidepressant Drugs
2.1.2 SSRIs
2.1.3 SNRIs
2.1.4 Benzodiazepines
2.1.5 Others
2.2 Global Major Depressive Disorder (MDD) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Major Depressive Disorder (MDD) Historic Market Size by Type (2018-2023)
2.2.2 Global Major Depressive Disorder (MDD) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Major Depressive Disorder (MDD) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Major Depressive Disorder (MDD) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Major Depressive Disorder (MDD) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Major Depressive Disorder (MDD) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Major Depressive Disorder (MDD) Revenue Breakdown by Type (2018-2029)
3 Major Depressive Disorder (MDD) Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Major Depressive Disorder (MDD) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Major Depressive Disorder (MDD) Historic Market Size by Application (2018-2023)
3.2.2 Global Major Depressive Disorder (MDD) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Major Depressive Disorder (MDD) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Major Depressive Disorder (MDD) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Major Depressive Disorder (MDD) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Major Depressive Disorder (MDD) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Major Depressive Disorder (MDD) Revenue Breakdown by Application (2018-2029)
4 Major Depressive Disorder (MDD) Competition Analysis by Players
4.1 Global Major Depressive Disorder (MDD) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Major Depressive Disorder (MDD) as of 2022)
4.3 Date of Key Players Enter into Major Depressive Disorder (MDD) Market
4.4 Global Top Players Major Depressive Disorder (MDD) Headquarters and Area Served
4.5 Key Players Major Depressive Disorder (MDD) Product Solution and Service
4.6 Competitive Status
4.6.1 Major Depressive Disorder (MDD) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Major Depressive Disorder (MDD) Products, Services and Solutions
5.1.4 Pfizer Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Profile
5.2.2 GlaxoSmithKline Main Business
5.2.3 GlaxoSmithKline Major Depressive Disorder (MDD) Products, Services and Solutions
5.2.4 GlaxoSmithKline Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.2.5 GlaxoSmithKline Recent Developments
5.3 Merck
5.3.1 Merck Profile
5.3.2 Merck Main Business
5.3.3 Merck Major Depressive Disorder (MDD) Products, Services and Solutions
5.3.4 Merck Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.3.5 AstraZeneca Recent Developments
5.4 AstraZeneca
5.4.1 AstraZeneca Profile
5.4.2 AstraZeneca Main Business
5.4.3 AstraZeneca Major Depressive Disorder (MDD) Products, Services and Solutions
5.4.4 AstraZeneca Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.4.5 AstraZeneca Recent Developments
5.5 Eli Lily
5.5.1 Eli Lily Profile
5.5.2 Eli Lily Main Business
5.5.3 Eli Lily Major Depressive Disorder (MDD) Products, Services and Solutions
5.5.4 Eli Lily Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.5.5 Eli Lily Recent Developments
5.6 Johnson & Johnson
5.6.1 Johnson & Johnson Profile
5.6.2 Johnson & Johnson Main Business
5.6.3 Johnson & Johnson Major Depressive Disorder (MDD) Products, Services and Solutions
5.6.4 Johnson & Johnson Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.6.5 Johnson & Johnson Recent Developments
5.7 Forest Laboratories
5.7.1 Forest Laboratories Profile
5.7.2 Forest Laboratories Main Business
5.7.3 Forest Laboratories Major Depressive Disorder (MDD) Products, Services and Solutions
5.7.4 Forest Laboratories Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.7.5 Forest Laboratories Recent Developments
5.8 Sanofi-Aventis
5.8.1 Sanofi-Aventis Profile
5.8.2 Sanofi-Aventis Main Business
5.8.3 Sanofi-Aventis Major Depressive Disorder (MDD) Products, Services and Solutions
5.8.4 Sanofi-Aventis Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.8.5 Sanofi-Aventis Recent Developments
5.9 H. Lundbeck
5.9.1 H. Lundbeck Profile
5.9.2 H. Lundbeck Main Business
5.9.3 H. Lundbeck Major Depressive Disorder (MDD) Products, Services and Solutions
5.9.4 H. Lundbeck Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.9.5 H. Lundbeck Recent Developments
5.10 Bristol-Myers Squibb
5.10.1 Bristol-Myers Squibb Profile
5.10.2 Bristol-Myers Squibb Main Business
5.10.3 Bristol-Myers Squibb Major Depressive Disorder (MDD) Products, Services and Solutions
5.10.4 Bristol-Myers Squibb Major Depressive Disorder (MDD) Revenue (US$ Million) & (2018-2023)
5.10.5 Bristol-Myers Squibb Recent Developments
6 North America
6.1 North America Major Depressive Disorder (MDD) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Major Depressive Disorder (MDD) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Major Depressive Disorder (MDD) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Major Depressive Disorder (MDD) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Major Depressive Disorder (MDD) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Major Depressive Disorder (MDD) Market Dynamics
11.1 Major Depressive Disorder (MDD) Industry Trends
11.2 Major Depressive Disorder (MDD) Market Drivers
11.3 Major Depressive Disorder (MDD) Market Challenges
11.4 Major Depressive Disorder (MDD) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
